Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/129811
DC FieldValue
dc.titleClinical applications of molecular genetics: The model of congenital adrenal hyperplasia
dc.contributor.authorLoke, K.Y.
dc.date.accessioned2016-11-08T09:58:50Z
dc.date.available2016-11-08T09:58:50Z
dc.date.issued2008-12
dc.identifier.citationLoke, K.Y. (2008-12). Clinical applications of molecular genetics: The model of congenital adrenal hyperplasia. Annals of the Academy of Medicine Singapore 37 (12 SUPPL.) : 18-21. ScholarBank@NUS Repository.
dc.identifier.issn03044602
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/129811
dc.description.abstractSpectacular advances in molecular genetics have enabled the molecular characterisation of many genetic disorders. The clinical applications include: (i) identification of pre-symptomatic and symptomatic affected individuals (monogenic diseases), allowing for early treatment and prevention of complications, (ii) carrier testing for genetic counselling, (iii) pharmacogenetic testing to guide medical treatment, and (iv) susceptibility testing (in polygenic diseases) to determine the risk of developing future disease. Using the model of congenital adrenal hyperplasia (CAH), direct mutational analysis can be applied to: (i) confirm the diagnosis when hormone assays have been equivocal, which would allow for early treatment and prevention of adrenal crisis, (ii) prenatal diagnosis and prenatal treatment in affected females to prevent or reduce prenatal virilisation, (iii) heterozygote carrier identification for genetic counselling, (iv) novel therapeutic applications to optimise treatment, including adjusting the steroid dose based on consistent genotype-phenotype correlations, so as to reduce the incidence of growth-inhibiting effects of steroid excess. However, molecular analysis can occasionally be complicated by multiple mutations on one allele, which may potentially affect genotype-phenotype correlations. Hence, molecular genetic analysis of CAH may eventually be adopted as a second tier confirmation of the disease, but is unlikely to replace the current first tier screening assays of precursor steroid metabolites proximal to the enzyme deficiency.
dc.sourceScopus
dc.subjectClinical applications
dc.subjectCongenital adrenal hyperplasia
dc.typeArticle
dc.contributor.departmentPAEDIATRICS
dc.description.sourcetitleAnnals of the Academy of Medicine Singapore
dc.description.volume37
dc.description.issue12 SUPPL.
dc.description.page18-21
dc.description.codenAAMSC
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

38
checked on Jun 23, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.